Text

Drug-Diagnostics Co-Development in Oncology

---

The idea of combining drugs and diagnostics in oncology is not new. When the selective estrogen-receptor modulator tamoxifen was developed in the 1970s for the treatment of breast cancer, data
on estrogen-receptor status were correlated with the treatment outcome. Based on a phase II study performed in patients with advanced breast cancer, published in 1976, the investigators concluded:“a
high degree of correlation between response and positive estrogen-receptor assay suggests the value of the diagnostic test as a means to select patients for tamoxifen treatment” (1). Despite the fact that this conclusion was drawn nearly 40 years ago, the
adaptation of the drug-diagnostic co-development model has been relatively slowand it is only within the last decade that it has gained widespread acceptance.

---

Availability

No copy data

Detail Information

Series Title

-

Call Number

615 DRU

Publisher

: Frontiers Media SA., 2014

Collation

-

Language

English

ISBN/ISSN

978-2-88919-332-5

Classification

615

Content Type

text

Media Type

computer

Carrier Type

online resource

Edition

-

Subject(s)

Drug-Diagnostics Co-Development in Oncology

Specific Detail Info

-

Statement of Responsibility

Penyunting, Jan Trøst Jørgensen

Other Information

Cataloger

Kholif Basri

Source

-

Validator

maya

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment